In addition to NSCLC and CRC, responses were also observed across a number of other tumour types, including HER2-expressing or HER2-amplified salivary gland cancer, biliary tract cancer, and endometrial cancer, and HER2-mutant non-amplified BC. Here, ERBB2 is linked to neoplasm.